Compare Stocks → Tiny Biotech Stock Wins $75 Billion Patent (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:AIFOTCMKTS:CAPCBATS:DJANNASDAQ:GRI Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIFApollo Tactical Income Fund$14.40$14.63$11.95▼$15.45N/AN/A142,403 shs111,536 shsCAPCCapstone Companies$0.01-14.2%$0.02$0.01▼$0.06$601K-0.3723,950 shs1,626 shsDJANFT Vest U.S. Equity Deep Buffer ETF - January$35.14-0.5%$35.65$0.00▼$0.00$259.34M0.48N/A2,389 shsGRIGRI Bio0.53+2.0%0.780.50▼115.50$1.69M-1.77625,344 shs424,131 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIFApollo Tactical Income Fund+0.70%+1.98%-4.32%-0.76%+15.57%CAPCCapstone Companies+16.53%+16.53%0.00%-42.91%-68.31%DJANFT Vest U.S. Equity Deep Buffer ETF - January-0.13%-1.60%-1.24%+1.89%+12.82%GRIGRI Bio+1.45%+1.45%-31.52%-72.62%+51,739,900.00%Tiny Biotech Stock Wins $75 Billion Patent (Ad)A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.Find out more here >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAIFApollo Tactical Income Fund3.233 of 5 stars3.04.00.00.03.80.80.0CAPCCapstone CompaniesN/AN/AN/AN/AN/AN/AN/AN/ADJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AN/AN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIFApollo Tactical Income Fund2.00Hold$52.50264.58% UpsideCAPCCapstone CompaniesN/AN/AN/AN/ADJANFT Vest U.S. Equity Deep Buffer ETF - January0.00N/AN/AN/AGRIGRI BioN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIFApollo Tactical Income Fund$36.81MN/AN/AN/AN/AN/ACAPCCapstone Companies$190K3.16N/AN/A($0.05) per share-0.24DJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/A0.40 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIFApollo Tactical Income FundN/AN/A0.00∞N/AN/AN/AN/AN/ACAPCCapstone Companies-$1.70M-$0.04N/A∞N/A-879.28%N/A-100.71%N/ADJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AN/A23.44∞N/AN/AN/AN/AN/AGRIGRI Bio-$13.04M-81.48N/A∞N/AN/A-795.54%-345.37%5/20/2024 (Estimated)Latest CAPC, DJAN, AIF, HLCL, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023CAPCCapstone CompaniesN/A-$0.01-$0.01-$0.01N/A$0.10 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIFApollo Tactical Income Fund$1.5110.49%+15.51%N/A2 YearsCAPCCapstone CompaniesN/AN/AN/AN/AN/ADJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AN/AN/AN/AN/AGRIGRI BioN/AN/AN/AN/AN/ALatest CAPC, DJAN, AIF, HLCL, and GRI DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/12/2024AIFApollo Tactical Income FundMonthly$0.144012.33%4/22/20244/23/20244/30/20243/11/2024AIFApollo Tactical Income FundMonthly$0.138011.04%3/20/20243/21/20243/28/20242/9/2024AIFApollo Tactical Income FundMonthly$0.133010.99%2/21/20242/22/20242/29/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIFApollo Tactical Income FundN/AN/AN/ACAPCCapstone CompaniesN/A0.020.02DJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AN/AN/AGRIGRI BioN/A1.091.09OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIFApollo Tactical Income FundN/ACAPCCapstone CompaniesN/ADJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AGRIGRI Bio33.95%Insider OwnershipCompanyInsider OwnershipAIFApollo Tactical Income FundN/ACAPCCapstone Companies40.00%DJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/AGRIGRI Bio16.82%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAIFApollo Tactical Income FundN/AN/AN/ANot OptionableCAPCCapstone Companies549.64 million29.79 millionNot OptionableDJANFT Vest U.S. Equity Deep Buffer ETF - JanuaryN/A7.38 millionN/ANot OptionableGRIGRI Bio13.20 million2.66 millionNot OptionableCAPC, DJAN, AIF, HLCL, and GRI HeadlinesSourceHeadlineGRI Bio, Inc.: GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patentfinanznachrichten.de - April 18 at 7:33 PMGRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patentglobenewswire.com - April 16 at 8:35 AMGRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conferenceglobenewswire.com - April 8 at 8:35 AMGRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Updateglobenewswire.com - April 1 at 7:35 AMTamil Nadu Newsprint & Papers Share Pricebusiness-standard.com - March 28 at 7:19 PMSteven Ehrlich donates professional archive to Architecture and Design Collection at UCSB’s AD&A Museumarchpaper.com - March 28 at 7:19 PMGRI Bio to Present at the MedInvest Biotech & Pharma Investor Conferenceglobenewswire.com - March 28 at 9:00 AMUCSB Art Museum Collection adds Archive of Modernist Architect Steven Ehrlichnoozhawk.com - March 18 at 9:11 PMProminent Modernist Steven Ehrlich Adds Architectural Archives to UC Santa Barbara Art Museumindependent.com - March 15 at 8:03 PMGRI Bio, Inc.: GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulatorsfinanznachrichten.de - March 14 at 1:50 PMGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulatorsfinance.yahoo.com - March 14 at 8:50 AMGRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulatorsglobenewswire.com - March 14 at 8:45 AMGRI Bio, Inc.: GRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdomfinanznachrichten.de - March 4 at 12:43 PMGRI Bio Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdomglobenewswire.com - March 4 at 8:30 AMTop 4 Health Care Stocks That Are Preparing To Pump This Month - ProSomnus (NASDAQ:OSA), GRI Bio (NASDAQ:GRI)benzinga.com - February 23 at 7:50 AMGRI Bio: Entry Into A Material Definitive Agreement, Other Eventscbonds.com - February 5 at 2:06 PMGRI Bio Launches Major Securities Public Offeringmsn.com - February 3 at 2:55 PMGRI Bio prices 5M shares at $1.10 in public offeringmsn.com - February 2 at 12:29 PMGRI Bio Shares Drop After Stock Offering Prices Below Thursday's Closemarketwatch.com - February 2 at 12:29 PMGRI Bio Announces Pricing Of $5.5 Mln Public Offering, Stock Downmarkets.businessinsider.com - February 2 at 12:29 PMWhy Is GRI Bio (GRI) Stock Down 21% Today?investorplace.com - February 2 at 11:07 AMSamsung Galaxy Fit3 tüm ayrıntılarıyla belli oldu: İşte özellikleridonanimhaber.com - January 31 at 12:56 PMGRI Bio, Inc.: GRI Bio Announces Reverse Stock Splitfinanznachrichten.de - January 26 at 7:25 PMGRI Bio's board OKs 1-for-7 reverse stock splitmsn.com - January 26 at 7:25 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsApollo Tactical Income FundNYSE:AIFApollo Tactical Income Fund Inc. is a closed-ended fixed income fund launched and managed by Apollo Credit Management, LLC. The fund invests in fixed income markets. It primarily invests in senior secured loans including floating rate senior loans, high yield corporate bonds, and other credit instruments of varying maturities made to companies whose debt is typically rated below investment grade. The fund employs a conservative approach to credit selection that focuses on such factors as collateral coverage, structural seniority, credit fundamentals, with emphasis on leading defensible market positions, stable companies with positive cash flow, and proven management teams to create its portfolio. Apollo Tactical Income Fund Inc. was formed on February 25, 2013 and is domiciled in the United States.Capstone CompaniesOTCMKTS:CAPCCapstone Companies, Inc., through its subsidiaries, engages in the development, marketing, and sale of consumer home light-emitting diode (LED) lighting products for indoor and outdoor applications worldwide. Its lighting products include connected surfacessmart mirrors and standard rectangular wardrobe/fitness mirrors. The company markets its products under the Capstone Lighting brand name, as well as under the Hoover Home LED brand through a network of direct sales force, retailers, and distributors. It sells its products through e-commerce websites. The company was formerly known as CHDT Corporation and changed its name to Capstone Companies, Inc. in June 2012. Capstone Companies, Inc. is headquartered in Deerfield Beach, Florida.FT Vest U.S. Equity Deep Buffer ETF - JanuaryBATS:DJANThe FT Cboe Vest U.S. Equity Deep Buffer ETF - January (DJAN) is an exchange-traded fund that is based on the SPDR S&P 500 ETF Trust index. The fund aims for specific buffered losses and capped gains on SPY ETF over a specific holdings period. The actively-managed fund holds options and collateral. DJAN was launched on Jan 15, 2021 and is managed by First Trust.GRI BioNASDAQ:GRIGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.